Business
TNI BioTech, Inc. Announces Further Agreement on Methionine-Enkephalin with Hubei Qianjiang Pharmaceutical Co., Ltd.
TNI BioTech, Inc. Announces Further Agreement on Methionine-Enkephalin with Hubei Qianjiang Pharmaceutical Co., Ltd..
About this update from Biostax Corp.
[{"type":"text","content":"\n\n\n\nTNI BioTech, Inc. Announces Further Agreement on Methionine-Enkephalin with Hubei Qianjiang Pharmaceutical Co., Ltd.\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nTNI BioTech, Inc. Announces Further Agreement on Methionine-Enkephalin with Hubei Qianjiang Pharmaceutical Co., Ltd.\nPR Newswire\nORLANDO, Fla., March 26, 2014\n\n\n\nORLANDO, Fla., March 26, 2014 /PRNewswire/ -- TNI BioTech, Inc. (OTC: TNIB), today announced that it has signed a 'Supplementary Cooperation Agreement (the \"Agreement\") on New Drug Methionine-Enkephalin' with Hubei Qianjiang Pharmaceutical Co., Ltd. (a Chinese listed company, hereinafter referred to as \"Qianjiang\"). \n\nFollowing TNI BioTech's FDA meeting in August of 2013, in which the FDA approved TNI BioTech to study Methionine-Enkephalin (\"MENK\") in clinical trials for pancreatic cancer advancing TNI BioTech's path to End of Phase II and the possibility of Phase III studies, Qianjiang has engaged in significant market research and pre-trials on pharmaceutical and pharma-toxicology studies, which suggest initial positive results.\n\nIn order to accelerate clinical trials in America and China, Qianjiang and TNI BioTech have agreed that Qianjiang will immediately start clinical trials in China. According to the previous agreements and as expanded by this latest Agreement, Qianjiang will provide funding for such studies and TNI BioTech will provide all its research materials, data, and results in America to Qianjiang and Qianjiang and TNI BioTech will seek registration for MENK in China. If and when manufacturing approval is achieved from the Chinese Government, Qianjiang will produce and sell MENK in China subject to the terms of a further agreement with TNI BioTech.\n\nIRT-101 (MENK) is an active immunotherapy with MENK for patients with deficient functioning of the immune system. It works by restoring the patient's immune functions and by activating the lymphocytes to attack cancer cells and infectious diseases, such as HIV/AIDS. This is accomplished because MENK binds to opioid receptors on both immune cells and on cancer...